TNF and cancer: Many therapeutic approaches targeting the TNF family, including CD40, OX40, 4-1BB, GITR, and CD27, are currently being actively investigated in clinical trials in various cancers, including GBM, lung cancer, malignant pleural mesothelioma, and spontaneous prostate cancer (7, 10–12).